GSK's COPD drug Nucala approved for market launch by the European Union
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Glonghui, February 6th｜GlaxoSmithKline announced today that the European Commission has approved its monoclonal antibody maintenance therapy drug Nucala for uncontrolled chronic obstructive pulmonary disease (COPD). GlaxoSmithKline stated that this approval is based on positive data from the MATINEE Phase III clinical trial. There are over 390 millions COPD patients worldwide, with approximately 40 millions in Europe.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
KelpDAO vulnerability causes DeFi TVL to decrease by 13 billion dollars
AIcoin•2026/04/26 16:03
Research shows that Polymarket's accuracy mainly comes from 3% of traders
AIcoin•2026/04/26 13:52
Iranian Official: Vessels Passing Through the Strait of Hormuz Must Pay Fee
BlockBeats•2026/04/26 13:23
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$78,077.75
+0.90%
Ethereum
ETH
$2,346.67
+1.71%
Tether USDt
USDT
$1
+0.02%
XRP
XRP
$1.43
+0.13%
BNB
BNB
$632.08
+0.36%
USDC
USDC
$0.9999
+0.01%
Solana
SOL
$86.58
+0.40%
TRON
TRX
$0.3239
+0.02%
Dogecoin
DOGE
$0.09897
+0.78%
Hyperliquid
HYPE
$41.34
-0.05%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now